Nanoparticle surface-enhanced Raman spectroscopy as a noninvasive, label-free tool to monitor hematological malignancy

Stacy Grieve; Nagaprasad Puvvada; Angkoon Phinyomark; Kevin Russell; Alli Murugesan; Elizabeth Zed; Ansar Hassan; Jean Francois Legare; Petra C Kienesberger; Thomas Pulinilkunnil; Tony Reiman; Erik Scheme; Keith R. Brunt

doi:10.2217/nnm-2021-0076

Nanoparticle surface-enhanced Raman spectroscopy as a noninvasive, label-free tool to monitor hematological malignancy

Stacy Grieve, Nagaprasad Puvvada, Angkoon Phinyomark, Kevin Russell, Alli Murugesan, Elizabeth Zed, Ansar Hassan, Jean Francois Legare, Petra C Kienesberger, Thomas Pulinilkunnil, Tony Reiman, Erik Scheme, Keith R. Brunt

Medicine

Producción científica: Contribución a una revista › Artículo › revisión exhaustiva

9 Citas (Scopus)

Resumen

Aim: Monitoring minimal residual disease remains a challenge to the effective medical management of hematological malignancies; yet surface-enhanced Raman spectroscopy (SERS) has emerged as a potential clinical tool to do so. Materials & methods: We developed a cell-free, label-free SERS approach using gold nanoparticles (nanoSERS) to classify hematological malignancies referenced against two control cohorts: healthy and noncancer cardiovascular disease. A predictive model was built using machine-learning algorithms to incorporate disease burden scores for patients under standard treatment upon. Results: Linear- and quadratic-discriminant analysis distinguished three cohorts with 69.8 and 71.4% accuracies, respectively. A predictive nanoSERS model correlated (MSE = 1.6) with established clinical parameters. Conclusion: This study offers a proof-of-concept for the noninvasive monitoring of disease progression, highlighting the potential to incorporate nanoSERS into translational medicine.

Idioma original	English
Páginas (desde-hasta)	2175-2188
Número de páginas	14
Publicación	Nanomedicine
Volumen	16
N.º	24
DOI	https://doi.org/10.2217/nnm-2021-0076
Estado	Published - oct. 2021

Nota bibliográfica

Funding Information:
The authors acknowledge the financial support from the Leukemia Lymphoma Society of Canada (TR, KB), New Brunswick Innovation Foundation (T Reiman, KR Brunt, Erik Scheme), Dalhousie Medical Research Foundation (K Russell, KR Brunt), National Science and Engineering Research Council (E Scheme, KR Brunt), Canadian Cancer Society, Research Chair (T Reiman), Canadian Institute of Health Research/New Brunswick Health Research Foundation, Mentorship Chair (T Reiman), and Terry Fox Research Institute (T Reiman). N Puvvada was supported through a Canadian Institute for Health Research – Strategy for Patient-Oriented Research and New Brunswick Health Research Foundation fellowship and an INSPIRE Faculty research grant from DST India. S Grieve was supported through a fellowship from Beatrice Hunter Cancer Research Institute, New Brunswick Health Research Foundation, and Lung Cancer Canada. KR Brunt holds an equity position in NB-BioMatrix Inc., a private sector company with financial interests derived from brokering knowledge and intellectual property including nanotechnology. Plasma samples and clinical characteristics from patients diagnosed with multiple myeloma, lymphoma or cardiovascular disease and treated at the Saint John Regional Hospital were collected with the approval of the Horizon Health Network Research Ethics Board. Plasma from the healthy control group was obtained from volunteer New Brunswick Community College (NBCC) students under approval from NBCC Research Ethics Review Board. The Au nanoparticles were characterized alone or in the presence of plasma by UV-Vis spectroscopy (BioTEK Synergy H4, cm-1 spectral resolution) and transmission electron microscopy (TEM; JEOL 2011 Scanning Transmission Electron Microscope, 50K resolution, University of New Brunswick). Twenty microliters of patient plasma was mixed with 25 μl of AuNPs and incubated at 37◦C for 2 min before transferring to a glass slide and allowed to dry. SERS spectra were measured using a Renishaw inVia Raman Spectrometer (University of New Brunswick Planetary and Space Science Centre) with a helium–neon laser beam with 514 excitation wavelength, at 10% laser power and 3 accumulations of spectra ranging from 100–2000 cm-1 after calibration of the instrument. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

Publisher Copyright:
© 2021 The Authors.

ASJC Scopus Subject Areas

Bioengineering
Medicine (miscellaneous)
Biomedical Engineering
General Materials Science

PubMed: MeSH publication types

Journal Article
Research Support, Non-U.S. Gov't

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

Acceder al documento

10.2217/nnm-2021-0076

Otros archivos y enlaces

Citar esto

Grieve, S., Puvvada, N., Phinyomark, A., Russell, K., Murugesan, A., Zed, E., Hassan, A., Legare, J. F., C Kienesberger, P., Pulinilkunnil, T., Reiman, T., Scheme, E., & Brunt, K. R. (2021). Nanoparticle surface-enhanced Raman spectroscopy as a noninvasive, label-free tool to monitor hematological malignancy. Nanomedicine, 16(24), 2175-2188. https://doi.org/10.2217/nnm-2021-0076

Grieve, S, Puvvada, N, Phinyomark, A, Russell, K, Murugesan, A, Zed, E, Hassan, A, Legare, JF, C Kienesberger, P , Pulinilkunnil, T, Reiman, T, Scheme, E & Brunt, KR 2021, 'Nanoparticle surface-enhanced Raman spectroscopy as a noninvasive, label-free tool to monitor hematological malignancy', Nanomedicine, vol. 16, n.º 24, pp. 2175-2188. https://doi.org/10.2217/nnm-2021-0076

@article{ee9ee93785d9459fa656179925a64b09,

title = "Nanoparticle surface-enhanced Raman spectroscopy as a noninvasive, label-free tool to monitor hematological malignancy",

abstract = "Aim: Monitoring minimal residual disease remains a challenge to the effective medical management of hematological malignancies; yet surface-enhanced Raman spectroscopy (SERS) has emerged as a potential clinical tool to do so. Materials & methods: We developed a cell-free, label-free SERS approach using gold nanoparticles (nanoSERS) to classify hematological malignancies referenced against two control cohorts: healthy and noncancer cardiovascular disease. A predictive model was built using machine-learning algorithms to incorporate disease burden scores for patients under standard treatment upon. Results: Linear- and quadratic-discriminant analysis distinguished three cohorts with 69.8 and 71.4% accuracies, respectively. A predictive nanoSERS model correlated (MSE = 1.6) with established clinical parameters. Conclusion: This study offers a proof-of-concept for the noninvasive monitoring of disease progression, highlighting the potential to incorporate nanoSERS into translational medicine.",

author = "Stacy Grieve and Nagaprasad Puvvada and Angkoon Phinyomark and Kevin Russell and Alli Murugesan and Elizabeth Zed and Ansar Hassan and Legare, {Jean Francois} and {C Kienesberger}, Petra and Thomas Pulinilkunnil and Tony Reiman and Erik Scheme and Brunt, {Keith R.}",

note = "Funding Information: The authors acknowledge the financial support from the Leukemia Lymphoma Society of Canada (TR, KB), New Brunswick Innovation Foundation (T Reiman, KR Brunt, Erik Scheme), Dalhousie Medical Research Foundation (K Russell, KR Brunt), National Science and Engineering Research Council (E Scheme, KR Brunt), Canadian Cancer Society, Research Chair (T Reiman), Canadian Institute of Health Research/New Brunswick Health Research Foundation, Mentorship Chair (T Reiman), and Terry Fox Research Institute (T Reiman). N Puvvada was supported through a Canadian Institute for Health Research – Strategy for Patient-Oriented Research and New Brunswick Health Research Foundation fellowship and an INSPIRE Faculty research grant from DST India. S Grieve was supported through a fellowship from Beatrice Hunter Cancer Research Institute, New Brunswick Health Research Foundation, and Lung Cancer Canada. KR Brunt holds an equity position in NB-BioMatrix Inc., a private sector company with financial interests derived from brokering knowledge and intellectual property including nanotechnology. Plasma samples and clinical characteristics from patients diagnosed with multiple myeloma, lymphoma or cardiovascular disease and treated at the Saint John Regional Hospital were collected with the approval of the Horizon Health Network Research Ethics Board. Plasma from the healthy control group was obtained from volunteer New Brunswick Community College (NBCC) students under approval from NBCC Research Ethics Review Board. The Au nanoparticles were characterized alone or in the presence of plasma by UV-Vis spectroscopy (BioTEK Synergy H4, cm-1 spectral resolution) and transmission electron microscopy (TEM; JEOL 2011 Scanning Transmission Electron Microscope, 50K resolution, University of New Brunswick). Twenty microliters of patient plasma was mixed with 25 μl of AuNPs and incubated at 37◦C for 2 min before transferring to a glass slide and allowed to dry. SERS spectra were measured using a Renishaw inVia Raman Spectrometer (University of New Brunswick Planetary and Space Science Centre) with a helium–neon laser beam with 514 excitation wavelength, at 10% laser power and 3 accumulations of spectra ranging from 100–2000 cm-1 after calibration of the instrument. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript. Publisher Copyright: {\textcopyright} 2021 The Authors.",

year = "2021",

month = oct,

doi = "10.2217/nnm-2021-0076",

language = "English",

volume = "16",

pages = "2175--2188",

journal = "Nanomedicine",

issn = "1743-5889",

publisher = "Future Medicine Ltd.",

number = "24",

}

TY - JOUR

T1 - Nanoparticle surface-enhanced Raman spectroscopy as a noninvasive, label-free tool to monitor hematological malignancy

AU - Grieve, Stacy

AU - Puvvada, Nagaprasad

AU - Phinyomark, Angkoon

AU - Russell, Kevin

AU - Murugesan, Alli

AU - Zed, Elizabeth

AU - Hassan, Ansar

AU - Legare, Jean Francois

AU - C Kienesberger, Petra

AU - Pulinilkunnil, Thomas

AU - Reiman, Tony

AU - Scheme, Erik

AU - Brunt, Keith R.

N1 - Funding Information: The authors acknowledge the financial support from the Leukemia Lymphoma Society of Canada (TR, KB), New Brunswick Innovation Foundation (T Reiman, KR Brunt, Erik Scheme), Dalhousie Medical Research Foundation (K Russell, KR Brunt), National Science and Engineering Research Council (E Scheme, KR Brunt), Canadian Cancer Society, Research Chair (T Reiman), Canadian Institute of Health Research/New Brunswick Health Research Foundation, Mentorship Chair (T Reiman), and Terry Fox Research Institute (T Reiman). N Puvvada was supported through a Canadian Institute for Health Research – Strategy for Patient-Oriented Research and New Brunswick Health Research Foundation fellowship and an INSPIRE Faculty research grant from DST India. S Grieve was supported through a fellowship from Beatrice Hunter Cancer Research Institute, New Brunswick Health Research Foundation, and Lung Cancer Canada. KR Brunt holds an equity position in NB-BioMatrix Inc., a private sector company with financial interests derived from brokering knowledge and intellectual property including nanotechnology. Plasma samples and clinical characteristics from patients diagnosed with multiple myeloma, lymphoma or cardiovascular disease and treated at the Saint John Regional Hospital were collected with the approval of the Horizon Health Network Research Ethics Board. Plasma from the healthy control group was obtained from volunteer New Brunswick Community College (NBCC) students under approval from NBCC Research Ethics Review Board. The Au nanoparticles were characterized alone or in the presence of plasma by UV-Vis spectroscopy (BioTEK Synergy H4, cm-1 spectral resolution) and transmission electron microscopy (TEM; JEOL 2011 Scanning Transmission Electron Microscope, 50K resolution, University of New Brunswick). Twenty microliters of patient plasma was mixed with 25 μl of AuNPs and incubated at 37◦C for 2 min before transferring to a glass slide and allowed to dry. SERS spectra were measured using a Renishaw inVia Raman Spectrometer (University of New Brunswick Planetary and Space Science Centre) with a helium–neon laser beam with 514 excitation wavelength, at 10% laser power and 3 accumulations of spectra ranging from 100–2000 cm-1 after calibration of the instrument. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript. Publisher Copyright: © 2021 The Authors.

PY - 2021/10

Y1 - 2021/10

N2 - Aim: Monitoring minimal residual disease remains a challenge to the effective medical management of hematological malignancies; yet surface-enhanced Raman spectroscopy (SERS) has emerged as a potential clinical tool to do so. Materials & methods: We developed a cell-free, label-free SERS approach using gold nanoparticles (nanoSERS) to classify hematological malignancies referenced against two control cohorts: healthy and noncancer cardiovascular disease. A predictive model was built using machine-learning algorithms to incorporate disease burden scores for patients under standard treatment upon. Results: Linear- and quadratic-discriminant analysis distinguished three cohorts with 69.8 and 71.4% accuracies, respectively. A predictive nanoSERS model correlated (MSE = 1.6) with established clinical parameters. Conclusion: This study offers a proof-of-concept for the noninvasive monitoring of disease progression, highlighting the potential to incorporate nanoSERS into translational medicine.

AB - Aim: Monitoring minimal residual disease remains a challenge to the effective medical management of hematological malignancies; yet surface-enhanced Raman spectroscopy (SERS) has emerged as a potential clinical tool to do so. Materials & methods: We developed a cell-free, label-free SERS approach using gold nanoparticles (nanoSERS) to classify hematological malignancies referenced against two control cohorts: healthy and noncancer cardiovascular disease. A predictive model was built using machine-learning algorithms to incorporate disease burden scores for patients under standard treatment upon. Results: Linear- and quadratic-discriminant analysis distinguished three cohorts with 69.8 and 71.4% accuracies, respectively. A predictive nanoSERS model correlated (MSE = 1.6) with established clinical parameters. Conclusion: This study offers a proof-of-concept for the noninvasive monitoring of disease progression, highlighting the potential to incorporate nanoSERS into translational medicine.

UR - http://www.scopus.com/inward/record.url?scp=85116647519&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85116647519&partnerID=8YFLogxK

U2 - 10.2217/nnm-2021-0076

DO - 10.2217/nnm-2021-0076

M3 - Article

C2 - 34547916

AN - SCOPUS:85116647519

SN - 1743-5889

VL - 16

SP - 2175

EP - 2188

JO - Nanomedicine

JF - Nanomedicine

IS - 24

ER -

Nanoparticle surface-enhanced Raman spectroscopy as a noninvasive, label-free tool to monitor hematological malignancy

Resumen

Nota bibliográfica

ASJC Scopus Subject Areas

PubMed: MeSH publication types

ODS de las Naciones Unidas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto